Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00123201 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
A Phase 2 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00123201 is a Phase 2 study that has completed, run by Solvay Pharmaceuticals.
The verdict
NCT00123201, a Phase 2 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The primary objective of this study is to evaluate the efficacy and safety of dronabinol MDI for the acute treatment of moderate to severe migraine headache.
Interventions
- DRUG Dronabinol MDI
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-09 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00123201
The ClinicalTrials.gov registry entry for NCT00123201 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dronabinol MDI is the first listed.
NCT00123201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00123201 about?
NCT00123201 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache". The primary objective of this study is to evaluate the efficacy and safety of dronabinol MDI for the acute treatment of moderate to severe migraine headache.
What is the current status of trial NCT00123201?
This trial is currently completed. It is a Phase 2 study. The study started on 2005-09. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00123201?
The interventions under investigation include: Dronabinol MDI (DRUG).
Who is sponsoring clinical trial NCT00123201?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.